Stocktoria
ARVINAS, INC. ARVN
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2018-09-27
ARVINAS, INC. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -45.1% | -95.0% | -511.5% | -200.3% | -351.5% |
| Net margin | -30.8% | -75.5% | -467.9% | -215.0% | -356.3% |
| FCF margin | -105.0% | -99.1% | -446.8% | -213.3% | 1034.9% |
| Return on assets | -11.3% | -18.2% | -28.2% | -22.3% | -12.1% |
| Return on equity | -18.6% | -35.4% | -55.7% | -50.0% | -24.4% |
| Debt / equity | 0.00× | 0.00× | 0.00× | 0.00× | 0.00× |
| Current ratio | 4.92 | 4.64 | 4.98 | 4.20 | 5.93 |
| Revenue growth | -0.3% | 235.5% | -40.3% | 145.1% | 106.9% |
Source: SEC EDGAR filings · CIK 0001655759 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.